Education
About Us
Working with TipRanks
Follow Us
Gyre Therapeutics (GYRE)
NASDAQ:GYRE
Total Valuation
Gyre Therapeutics has a market cap or net worth of $610.78M. The enterprise value is $574.65M.
Market Cap$610.78M
Enterprise Value$574.65M
Share Statistics
Gyre Therapeutics has 90,890,380 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding90,890,380
Owned by Insiders3.87%
Owned by Institutions<0.01%
Financial Efficiency
Gyre Therapeutics’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 7.74%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)7.74%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee201.36K
Profits Per Employee17.06K
Employee Count579
Asset Turnover0.70
Inventory Turnover0.53
Valuation Ratios
The current PE Ratio of Gyre Therapeutics is 33.2. Gyre Therapeutics’s PEG ratio is -2.10.
PE Ratio33.2
PS Ratio5.41
PB Ratio5.95
Price to Fair Value5.95
Price to FCF-3.50K
Price to Operating Cash Flow606.50
PEG Ratio-2.10
Income Statement
In the last 12 months, Gyre Therapeutics had revenue of 116.59M and earned 5.03M in profits. Earnings per share was 0.06.
Revenue116.59M
Gross Profit111.17M
Operating Income11.49M
Pretax Income14.44M
Net Income5.03M
EBITDA14.01M
Earnings Per Share (EPS)0.06
Cash Flow
In the last 12 months, operating cash flow was 1.01M and capital expenditures -1.93M, giving a free cash flow of -917.00K billion.
Operating Cash Flow1.01M
Free Cash Flow-917.00K
Free Cash Flow per Share-0.01
Dividends & Yields
Gyre Therapeutics pays an annual dividend of $3.6, resulting in a dividend yield of ―
Dividend Per Share$3.6
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.87
52-Week Price Change-27.04%
50-Day Moving Average7.92
200-Day Moving Average7.75
Relative Strength Index (RSI)34.71
Average Volume (3m)102.52K
Important Dates
Gyre Therapeutics upcoming earnings date is May 8, 2026, TBA (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 8, 2026
Ex-Dividend Date―
Financial Position
Gyre Therapeutics as a current ratio of 5.60, with Debt / Equity ratio of 0.89%
Current Ratio5.60
Quick Ratio5.04
Debt to Market Cap<0.01
Net Debt to EBITDA-2.58
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Gyre Therapeutics has paid -4.56M in taxes.
Income Tax-4.56M
Effective Tax Rate-0.32
Enterprise Valuation
Gyre Therapeutics EV to EBITDA ratio is 42.44, with an EV/FCF ratio of -3.30K.
EV to Sales5.10
EV to EBITDA42.44
EV to Free Cash Flow-3.30K
EV to Operating Cash Flow588.75
Balance Sheet
Gyre Therapeutics has $52.42M in cash and marketable securities with $939.00K in debt, giving a net cash position of $51.49M billion.
Cash & Marketable Securities$52.42M
Total Debt$939.00K
Net Cash$51.49M
Net Cash Per Share$0.57
Tangible Book Value Per Share$1.54
Margins
Gross margin is 95.35%, with operating margin of 9.85%, and net profit margin of 4.31%.
Gross Margin95.35%
Operating Margin9.85%
Pretax Margin12.38%
Net Profit Margin4.31%
EBITDA Margin12.02%
EBIT Margin9.86%
Analyst Forecast
The average price target for Gyre Therapeutics is $19.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$19.00
Price Target Upside179.00% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―